

May 6, 2024

Dear Pharmaceutical Manufacturer:

Arizona's Medicaid Program, the Arizona Health Care Cost Containment System (AHCCCS), has contracted with Magellan Medicaid Administration, Inc. to secure supplemental rebates for preferred agents on the AHCCCS Drug List. The AHCCCS Drug List is utilized by both the Fee-For-Service and Managed Care Organization (MCO) programs.

The intent of AHCCCS is to accrue rebates on both Fee-For-Service and Managed Care utilization for preferred agents under the AHCCCS drug list which is managed by the AHCCCS for covered outpatient drugs dispensed to persons eligible in Arizona for Medicaid, the Children's Health Insurance Program and to persons with Serious Mental Illness, as defined in A.R.S. 36-550, who qualify for state funded care under A.R.S. 36-3408. The AHCCCS supplemental rebate agreement, drafted with the express purpose of establishing a single drug list and described further in section 2.1 of the ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM SUPPLEMENTAL DRUG-REBATE AGREEMENT (SRA), was approved by CMS on May 28, 2015:

2.1 It is the intent of this Agreement that the State will receive Supplemental Rebates, in addition to the rebates received under Manufacturer's CMS Agreement, pursuant to Section 1927 of the Social Security Act (42 U.S.C. §1396r-8), for the Manufacturer's Supplemental Covered Product(s) quarterly utilization in the Arizona Medicaid Program, including all Fee-For-Service and Managed Care beneficiaries, in which there is Medicaid federal financial participation. The parties also intend for this Agreement to meet the requirements of federal law at Section 1927 of the Social Security Act (42 U.S.C. §1396r-8).

At this time, supplemental rebate offers are requested for the following products and therapeutic categories which will be reviewed at the Pharmacy and Therapeutics Committee meeting.

**The P&T Meeting has been postponed due to information needed from CMS and the meeting has been rescheduled for June 18th from 12 Noon to 5 PM.**

**If your company has submitted a supplemental rebate offer, it is not necessary to resubmit a new supplemental rebate offer.**

**For new supplemental rebate offers, please submit by 05/17/2024.**

1. Analgesics, Long-Acting Narcotic
2. Antibiotics, Inhaled
3. Antimigraine Agents, Other
4. Antipsychotics, Atypical Long-Acting Injectable
5. Antipsychotics, Oral Atypical (2nd Generation Only)
6. COPD Agents
7. Cytokine and CAM Antagonists
8. Glucagon Agents
9. Glucocorticoids, Inhaled
10. Growth Hormone
11. Hepatitis C Agents

12. Hypoglycemics (Insulin and Related Agents)
13. Hypoglycemics, Incretin Mimetics/Enhancers
14. Immunologics (Immunomodulators, Atopic Dermatitis and Immunomodulators, Asthma)
15. Opioid Dependence Treatments
16. Pancreatic Enzymes
17. Stimulants and Related Agents

Supplemental rebate offers may be requested for additional products and/or other therapeutic categories in the future.

Supplemental rebates will begin to accrue on October 1, 2024 and end September 30, 2025 for those drugs selected as preferred.

**Due to time constraints of the meeting and the number of public testimony requests already received, we are unable to accept any additional requests from pharmaceutical manufacturers and related entities as well as any other public testimony requests.**

We hope that you will take this opportunity to participate in a program that seeks to retain access to quality pharmaceuticals for Arizona's most vulnerable citizens.

Sincerely,

A handwritten signature in blue ink, appearing to read 'Carmen Heredia', with a stylized flourish at the end.

Carmen Heredia  
Director